Press Releases

Nov 02, 2022

Veracyte Announces Third Quarter 2022 Financial Results

Read More

Nov 01, 2022

Veracyte Announces Three Abstracts to Be Presented at SITC 2022 Annual Meeting

Read More

Oct 27, 2022

Veracyte to Participate in the Credit Suisse 31st Annual Healthcare Conference

Read More

Oct 25, 2022

New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy

Read More

Oct 24, 2022

Veracyte Data Presented at ATA Annual Meeting Provide New Insights into Molecular Underpinnings of Thyroid Cancer

Read More

Oct 18, 2022

New Data Presented at CHEST 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer

Read More

Oct 13, 2022

Veracyte to Release Third Quarter 2022 Financial Results on November 2, 2022

Read More

Sep 22, 2022

New Data Published in JNCI Demonstrate Veracyte’s Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men

Read More

Sep 13, 2022

Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access

Read More

Sep 11, 2022

New Data Presented at ESMO 2022 Show Veracyte’s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer

Read More